Skip to content

    Arthritis Health Center

    Font Size

    FDA Panel Rejects Gout Drug on Safety Concerns

    Advisory Committee Votes Against Approval of the Gout Drug Ilaris
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    June 21, 2011 -- Safety concerns led an FDA advisory to oppose approval of new drug for gout on Tuesday, despite widespread enthusiasm for the medication's effectiveness against the painful disorder.

    The recommendation is likely to push the FDA to hold off on approving the drug, known by the brand name Ilaris, until manufacturers can prove it's safe for long-term use.

    The FDA is not required to accept the decision of its advisory panel, but it often does.

    Ilaris is an anti-inflammatory drug that studies show can relieve painful gout attacks in patients with gouty arthritis. It's delivered by injection whenever patients have gout flare-ups, which sometimes occur every two to three months or so.

    Manufacturers wanted to market the drug, known generically as canakinumab, for gouty arthritis patients who don't get gout relief from other available medications. Novartis, which makes the drug, estimated that about 300,000 U.S. patients would qualify.

    Gout occurs when uric acid builds up in the blood, crystallizes, and forms deposits in the joints. It can be extremely painful, and surrounding inflammation can damage adjacent tissue.

    Questions About Safety

    Studies conducted by manufacturer Novartis showed the drug significantly reduced the pain of gout attacks in most patients and also cut the chances that a gout attack would resurface over the next couple of months.

    "We continue to believe in the benefits of [Ilaris] for this painful and debilitating disease and will work closely with the FDA to identify the right patient population who will benefit from this therapy," Trevor Mundel, MD, global head of development at Novartis Pharmaceuticals, says in a news release. "We are encouraged by the committee's enthusiasm and robust discussion and remain committed to addressing the needs of people with gouty arthritis."

    The panel voted to reject the drug largely because Novartis only studied the drug for 12 weeks in its two largest trials. But the drug stays in the body for at least a month after each dose, and that left a lot of unanswered questions about how safe Ilaris is when patients take it over the course of several years.

    Today on WebMD

    Mature woman exercise at home
    Hint: Warming up first is crucial.
    feet with gout
    Quiz yourself.
    woman in pain
    One idea? Eat fish to curb inflammation.
    senior couple walking
    Can you keep your RA from progressing?
    xray of knees with osteoarthritis
    close up of man wearing dress shoes
    feet with gout
    close up of red shoe in shoebox
    two male hands
    Woman massaging her neck
    5 Lupus Risk Factors